PRACTICAL ONCOLOGY JOURNAL ›› 2015, Vol. 29 ›› Issue (2): 188-192.doi: 10.11904/j.issn.1002-3070.2015.02.020

• Review • Previous Articles    

Progress of targeted therapy in Her-2 positive gastric cancer

LI Sen,LI Zhiguo,CHENG Long,XUE Yingwei   

  1. Department of Gastrointestinal Surgery,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China
  • Received:2014-10-21 Online:2015-04-28 Published:2015-05-05

Abstract: Although chemotherapy is an effective way for advanced gastric cancer,it does not significantly improve the prognosis of patients.Recently,further researches on the mechanism of gastric cancer have led to the identification of ′driver gene′and the development of new agents that target these genes.By inhibiting the human epidermal growth factor receptor 2(Her-2)for advanced gastric cancer,it provides a new treatment for patients.Trastuzumab is a kind of Her-2 monoclonal antibody,it is the first kind of targeted therapy drug for the treatment of advanced and metastatic gastric cancer.A combination of trastuzumab with cisplatin and fluorouracil based chemotherapy can benefit patients overall survival.Therefore,in this paper,we make a review and summary of a set of recent studies related to the gastric targeted therapy.

CLC Number: